A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Elizabeth Challenger; Sujan Dilly-Penchala; Colin Hale; Richard Fitzgerald; Helen Reynolds; Justin Chiong; Tim Rowland; Tom Fletcher; Saye Khoo; Laura Else

doi:10.1016/j.jpba.2024.116155

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Elizabeth Challenger
, Sujan Dilly-Penchala
, Colin Hale
, Richard Fitzgerald
, Helen Reynolds
, Justin Chiong
, Tim Rowland
, Tom Fletcher
, Saye Khoo
, Laura Else

Clinical Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Favipiravir is a broad-spectrum antiviral that is metabolised intracellularly into the active form, favipiravir ribofuranosyl-5'-triphosphate (F-RTP). Measurement of the intracellular concentration of F-RTP in mononuclear cells is a crucial step to characterising the pharmacokinetics of F-RTP and to enable more appropriate dose selection for the treatment of COVID-19 and emerging infectious diseases. The described method was validated over the range 24 - 2280 pmol/sample. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lysed using methanol-water (70:30, v/v) before cellular components were precipitated with acetonitrile and the supernatant further cleaned by weak anion exchange solid phase extraction. The method was found to be both precise and accurate and was successfully utilised to analyse F-RTP concentrations in patient samples collected as part of the AGILE CST-6 clinical trial.

Original language	English
Article number	116155
Pages (from-to)	116155
Journal	Journal of Pharmaceutical and Biomedical Analysis
Volume	245
DOIs	https://doi.org/10.1016/j.jpba.2024.116155
Publication status	Published - 21 Apr 2024

Keywords

Bioanalysis
COVID-19
Favipiravir RTP
SARS-CoV-2
T-705 RTP

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jpba.2024.116155Licence: CC BY

1-s2Final published version, 1 MBLicence: CC BY

Cite this

Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., Rowland, T., Fletcher, T., Khoo, S., & Else, L. (2024). A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells. Journal of Pharmaceutical and Biomedical Analysis, 245, 116155. Article 116155. https://doi.org/10.1016/j.jpba.2024.116155

@article{1fdb9ab7602b49d8ac29c51801471403,

title = "A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.",

abstract = "Favipiravir is a broad-spectrum antiviral that is metabolised intracellularly into the active form, favipiravir ribofuranosyl-5'-triphosphate (F-RTP). Measurement of the intracellular concentration of F-RTP in mononuclear cells is a crucial step to characterising the pharmacokinetics of F-RTP and to enable more appropriate dose selection for the treatment of COVID-19 and emerging infectious diseases. The described method was validated over the range 24 - 2280 pmol/sample. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lysed using methanol-water (70:30, v/v) before cellular components were precipitated with acetonitrile and the supernatant further cleaned by weak anion exchange solid phase extraction. The method was found to be both precise and accurate and was successfully utilised to analyse F-RTP concentrations in patient samples collected as part of the AGILE CST-6 clinical trial.",

keywords = "Bioanalysis, COVID-19, Favipiravir RTP, SARS-CoV-2, T-705 RTP",

author = "Elizabeth Challenger and Sujan Dilly-Penchala and Colin Hale and Richard Fitzgerald and Helen Reynolds and Justin Chiong and Tim Rowland and Tom Fletcher and Saye Khoo and Laura Else",

year = "2024",

month = apr,

day = "21",

doi = "10.1016/j.jpba.2024.116155",

language = "English",

volume = "245",

pages = "116155",

journal = "Journal of Pharmaceutical and Biomedical Analysis",

issn = "0731-7085",

publisher = "Elsevier B.V.",

}

Challenger, E, Dilly-Penchala, S, Hale, C, Fitzgerald, R, Reynolds, H, Chiong, J, Rowland, T , Fletcher, T, Khoo, S & Else, L 2024, 'A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.', Journal of Pharmaceutical and Biomedical Analysis, vol. 245, 116155, pp. 116155. https://doi.org/10.1016/j.jpba.2024.116155

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells. / Challenger, Elizabeth; Dilly-Penchala, Sujan; Hale, Colin et al.
In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 245, 116155, 21.04.2024, p. 116155.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

AU - Challenger, Elizabeth

AU - Dilly-Penchala, Sujan

AU - Hale, Colin

AU - Fitzgerald, Richard

AU - Reynolds, Helen

AU - Chiong, Justin

AU - Rowland, Tim

AU - Fletcher, Tom

AU - Khoo, Saye

AU - Else, Laura

PY - 2024/4/21

Y1 - 2024/4/21

N2 - Favipiravir is a broad-spectrum antiviral that is metabolised intracellularly into the active form, favipiravir ribofuranosyl-5'-triphosphate (F-RTP). Measurement of the intracellular concentration of F-RTP in mononuclear cells is a crucial step to characterising the pharmacokinetics of F-RTP and to enable more appropriate dose selection for the treatment of COVID-19 and emerging infectious diseases. The described method was validated over the range 24 - 2280 pmol/sample. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lysed using methanol-water (70:30, v/v) before cellular components were precipitated with acetonitrile and the supernatant further cleaned by weak anion exchange solid phase extraction. The method was found to be both precise and accurate and was successfully utilised to analyse F-RTP concentrations in patient samples collected as part of the AGILE CST-6 clinical trial.

AB - Favipiravir is a broad-spectrum antiviral that is metabolised intracellularly into the active form, favipiravir ribofuranosyl-5'-triphosphate (F-RTP). Measurement of the intracellular concentration of F-RTP in mononuclear cells is a crucial step to characterising the pharmacokinetics of F-RTP and to enable more appropriate dose selection for the treatment of COVID-19 and emerging infectious diseases. The described method was validated over the range 24 - 2280 pmol/sample. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lysed using methanol-water (70:30, v/v) before cellular components were precipitated with acetonitrile and the supernatant further cleaned by weak anion exchange solid phase extraction. The method was found to be both precise and accurate and was successfully utilised to analyse F-RTP concentrations in patient samples collected as part of the AGILE CST-6 clinical trial.

KW - Bioanalysis

KW - COVID-19

KW - Favipiravir RTP

KW - SARS-CoV-2

KW - T-705 RTP

U2 - 10.1016/j.jpba.2024.116155

DO - 10.1016/j.jpba.2024.116155

M3 - Article

SN - 0731-7085

VL - 245

SP - 116155

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

M1 - 116155

ER -

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this